BCR-ABL1 L248V
|
CML
|
BCR-ABL1 L248V
|
CML
|
dasatinib Sensitive: B - Late Trials
|
dasatinib Sensitive: B - Late Trials
|
BCR-ABL1 L248V
|
CML
|
BCR-ABL1 L248V
|
CML
|
imatinib Resistant: C3 – Early Trials
|
imatinib Resistant: C3 – Early Trials
|
BCR-ABL1 L248V
|
CML
|
BCR-ABL1 L248V
|
CML
|
bosutinib Sensitive: C3 – Early Trials
|
bosutinib Sensitive: C3 – Early Trials
|
BCR-ABL1 L248V
|
CML
|
BCR-ABL1 L248V
|
CML
|
dasatinib + imatinib + nilotinib Resistant: D – Preclinical
|
dasatinib + imatinib + nilotinib Resistant: D – Preclinical
|
BCR-ABL1 L248V
|
CML
|
BCR-ABL1 L248V
|
CML
|
nilotinib Sensitive: D – Preclinical
|
nilotinib Sensitive: D – Preclinical
|